Inkvivo

InkVivo Technologies SA is a Swiss-based company operating at the intersection of medtech and advanced manufacturing. The company was formally established in January 2023 as a spin-off from ETH Zürich, building on over five years of dedicated research. The founding team, which includes CEO Dr. Elia Guzzi, CTO Leonardo Tognola, and COO Stefano Cerutti, combined their expertise in biomedical engineering and business to translate academic research into commercial products starting in 2020. Dr. Guzzi's doctoral work in mechanical and biomedical engineering at ETH Zurich laid the technical foundation for the company's core platform.

The firm's central business is the development and fabrication of advanced drug delivery systems. InkVivo utilizes a patented biomaterial platform combined with scalable manufacturing techniques to produce systems that provide controlled, localized, and time-regulated release of active ingredients such as small molecules, biologics, and micronutrients. This technology enables the precise design of 3D-printed, implantable, and resorbable products. A primary application is a subdermal patch for post-operative care that releases analgesics and anti-inflammatory drugs over several days, aiming to reduce patient pain and administration frequency.

InkVivo operates on a business-to-business model, establishing partnerships with pharmaceutical, nutraceutical, and cosmetic companies. The company offers its platform to co-develop novel therapies, repurpose and reformulate existing drugs, and extend the patent lifecycle of its partners' products. This approach provides a strategic service to clients by creating new value from their existing assets. The business primarily generates revenue through these collaborative development partnerships. The company has gained early recognition, winning the Boldbrain Startup Challenge and the Scouting for Innovation contest in 2021 and securing pre-seed funding.

Keywords: drug delivery systems, biomaterial platform, advanced manufacturing, controlled release, temporal release, pharmaceutical partnerships, nutraceutical applications, medtech, ETH Zurich spin-off, drug reformulation, patent lifecycle extension, bio-ink, 3D bioprinting, resorbable implants, post-operative pain management, Elia Guzzi, biomedical engineering, targeted therapy, small molecule delivery, biologics delivery